CDMOs offering HPAPI Manufacturing (High-Potency) with Peptide
16 published
16 published CDMOs match HPAPI Manufacturing (High-Potency) and Peptide.
Locations in this set include United States, United Kingdom, China, India, Ireland, and Italy.
Capabilities that show up most often in this set: API Synthesis & Manufacturing, CMC Analytical Development, Process Development, Peptide Manufacturing, and Technology Transfer.
Matching companies
Almac GroupGlobal CDMO with 7,900+ employees across 18 facilities, offering integrated drug development and manufacturing services including analytical development, formulation, process development, fill-finish, and specialized chemistry capabilities.- Asymchem LaboratoriesAsymchem is a CDMO providing integrated API synthesis, drug product development, and biologics manufacturing with specialized capabilities in peptides, oligonucleotides, highly potent compounds, and flow chemistry.
- BSP PharmaceuticalsBSP Pharmaceuticals is a CDMO specializing in development and manufacturing of cytotoxic oncology drugs, ADCs, peptides, proteins, and lipid-based formulations from preclinical GLP through commercial supply.
CambrexCDMO offering drug substance and drug product development, manufacturing, and analytical services across small molecules, peptides, and specialty chemistries.
CordenPharmaFull-service CDMO offering cGMP development and manufacturing of APIs, lipid excipients, drug products, injectables, peptides, LNPs, oligonucleotides, and oral solid dose across 10 facilities in 6 countries with 3000+ employees.
CuriaGlobal CDMO with 30+ years of experience offering integrated services across small molecule, generic APIs, sterile drug product, and biologics manufacturing, backed by 20+ facilities and 3,000+ professionals across North America, Europe, and India.
Dalton Pharma ServicesHealth Canada–approved and FDA-inspected cGMP contract manufacturer offering integrated drug discovery, development, and manufacturing services including custom synthesis, API production, formulation development, and sterile fill-finish for vials, syringes, and cartridges.
Divi's LaboratoriesWorld's largest API manufacturer and trusted CDMO partner for 25+ years, offering generic APIs, custom synthesis, peptides, and nutraceutical ingredients to 100+ countries with complete backward integration and green chemistry principles.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Piramal Pharma SolutionsCDMO specializing in HPAPIs, ADCs, peptides, vaccines, and biologics with 4,700+ team members across 15 global sites and 500+ customers. Offers integrated development and manufacturing with backward integration capabilities and global program management.
Quotient SciencesIntegrated CDMO offering drug product formulation and manufacturing for small molecules and synthetic peptides, with 30+ years of experience and scalable capacity from clinical to 500 kg commercial batches across US and UK facilities.
SK pharmtecoSK pharmteco is a CDMO offering comprehensive drug development and manufacturing services.
Sterling Pharma SolutionsSmall molecule CDMO offering comprehensive API development and manufacturing from discovery through commercial cGMP production, with specialized expertise in complex and hazardous chemistries and ADC bioconjugation.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
VeranovaGlobal CDMO specializing in development and manufacturing of complex active pharmaceutical ingredients (APIs), with expertise in solid form sciences, process development, and specialty modalities including ADCs and controlled substances.- 重庆兴泰濠制药有限公司 (Sintaho)China-based API and CDMO/CMO supplier focused on cytotoxic and OEB5 high-potency APIs, peptides, and XDC compounds. Reports FDA on-site inspections in 2024 and 2025 and product registrations in more than 30 countries.
Markdown mirror: /explore/hpapi-manufacturing/peptide.md